Processing

Please wait...

Settings

Settings

1. WO2020000101 - INFLUENZA VIRUS HEMAGGLUTININ MUTANTS

Publication Number WO/2020/000101
Publication Date 02.01.2020
International Application No. PCT/CA2019/050893
International Filing Date 27.06.2019
IPC
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
31
Genes encoding microbial proteins, e.g. enterotoxins
33
Genes encoding viral proteins
40
Proteins from RNA viruses, e.g. flaviviruses
44
Orthomyxoviridae, e.g. influenza virus
A HUMAN NECESSITIES
01
AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
H
NEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
5
Flowering plants, i.e. angiosperms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
145
Orthomyxoviridae, e.g. influenza virus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
16
for influenza or rhinoviruses
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
04
Immunostimulants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
08
RNA viruses
11
Orthomyxoviridae, e.g. influenza virus
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08
against material from viruses
10
from RNA viruses
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
82
for plant cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01
Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
C12N 15/44 (2006.01)
A01H 5/00 (2018.01)
A61K 39/145 (2006.01)
A61P 31/16 (2006.01)
A61P 37/04 (2006.01)
C07K 14/11 (2006.01)
CPC
A61K 39/145
A61P 31/16
A61P 37/04
C07K 14/11
C07K 16/10
C12N 15/8258
Applicants
  • MEDICAGO INC. [CA/CA]; 600 - 1020 Route de l'Eglise Quebec, Québec G1V 3V9, CA
Inventors
  • LAVOIE, Pierre-Olivier; CA
  • LORIN, Aurélien; CA
  • DOUCET, Alain; CA
  • D'AOUST, Marc-André; CA
  • COUTURE, Manon; CA
Agents
  • SECHLEY, Konrad; CA
  • ZIESCHE, Sonia; CA
  • KINGWELL, Brian; CA
  • THORNE, Lisa; CA
  • RIPLEY, Roch; CA
  • LEE, Brian; CA
  • WILKE, Mark; CA
  • SALISBURY, Clare; CA
Priority Data
62/690,78027.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INFLUENZA VIRUS HEMAGGLUTININ MUTANTS
(FR) MUTANTS D'HÉMAGGLUTININE DU VIRUS DE LA GRIPPE
Abstract
(EN)
The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.
(FR)
La présente invention concerne la production de protéines virales de la grippe modifiées dans des plantes. Plus spécifiquement, la présente invention concerne la production et l'augmentation de la production de particules de type virus (VLP) de la grippe dans des plantes, les VLP comprenant les protéines virales de la grippe modifiées, telles que l'hémagglutinine (HA) de la grippe modifiée. La protéine HA peut comprendre une séquence d'acides aminés comportant au moins une substitution par rapport à une séquence d'acides aminés de type sauvage correspondante. L'invention concerne en outre un acide nucléique codant pour la protéine HA modifiée. L'invention porte en outre sur des procédés de production d'une particule de type virus (VLP) de la grippe et sur des procédés d'augmentation du rendement de production d'une particule de type virus (VLP) de la grippe dans une plante, une partie d'une plante ou une cellule végétale.
Latest bibliographic data on file with the International Bureau